Health Condition 1: J45- Asthma
Conditions
Interventions
Intervention1: Nil: Nil
Sponsors
Cipla Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1 Either gender, of age 18 years or above, with documented diagnosis of Asthma (as per GINA 2025) 2 Prescribed treatment with ICS-LABA delivered through the Ciphaler based on investigator discretion 3 Willing for follow-up at scheduled visit as per protocol 4 A voluntarily given written, signed, dated informed consent from participants and/or legally acceptable representative
Exclusion criteria
Exclusion criteria: 1 Hypersensitivity to the study drug or any of its components 2 Life-threatening or unstable respiratory disease, including lower respiratory tract infection, within the past 4 weeks from screening 3 Acute episodes of asthma requiring systemic corticosteroids, emergency care or hospitalization in the 30 days prior to Baseline visit 4 Chronic pulmonary diseases other than asthma such as COPD, post-tuberculosis lung disease, pulmonary fibrotic disease, or pulmonary arterial hypertension 5 Severe asthma patients receiving biologicals
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient satisfactionTimepoint: 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Ease of training with Ciphaler Timepoint: Baseline;2. Change in ACQ-5 scoreTimepoint: Baseline Week 8;3. Change in ACQ-5 score categories as well controlled (ACQ-5 less than 0.75), partially controlled (ACQ-5 more than 0.75 to less than 1.5), and uncontrolled (ACQ-5 more than 1.5)Timepoint: Baseline week 8;4. Adverse EventTimepoint: Through Study | — |
Countries
India
Contacts
Public ContactVaishali Naik
Cipla Ltd
Outcome results
None listed